360 related articles for article (PubMed ID: 36322878)
1. Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD.
Buxbaum NP; Socié G; Hill GR; MacDonald KPA; Tkachev V; Teshima T; Lee SJ; Ritz J; Sarantopoulos S; Luznik L; Zeng D; Paczesny S; Martin PJ; Pavletic SZ; Schultz KR; Blazar BR
Blood Adv; 2023 Sep; 7(17):4886-4902. PubMed ID: 36322878
[TBL] [Abstract][Full Text] [Related]
2. Incidence and Outcome of Atypical Manifestations of Chronic Graft-versus-Host Disease: Results From a Retrospective Single-Center Analysis.
Doering J; Perl M; Weber D; Banas B; Schulz C; Hamer OW; Angstwurm K; Holler E; Herr W; Edinger M; Wolff D; Fante MA
Transplant Cell Ther; 2023 Dec; 29(12):772.e1-772.e10. PubMed ID: 37777112
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on oral chronic graft-versus-host disease from immunobiology to morbid diagnoses.
Tollemar V; Garming Legert K; Sugars RV
Front Immunol; 2023; 14():1151493. PubMed ID: 37449200
[TBL] [Abstract][Full Text] [Related]
4. Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development.
Kim DDH; Popradi G; Lepic K; Paulson K; Allan D; Nampoothiri RV; Lachance S; Deotare U; White J; Elemary M; Jamani K; Fraga C; Lemieux C; Novitzky-Basso I; Law AD; Kumar R; Walker I; Schultz KR;
Curr Oncol; 2024 Mar; 31(3):1426-1444. PubMed ID: 38534941
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic response of oral chronic graft-versus-host disease to topical corticosteroids according to the 2014 National Institutes of Health (USA) consensus criteria.
Siripornkitti W; Pengpis N; Chanswangphuwana C; Prueksrisakul T
Med Oral Patol Oral Cir Bucal; 2024 Mar; 29(2):e219-e226. PubMed ID: 37823294
[TBL] [Abstract][Full Text] [Related]
6. Chronic graft-versus-host disease. Part II: Disease activity grading and therapeutic management.
Baumrin E; Loren AW; Falk SJ; Mays JW; Cowen EW
J Am Acad Dermatol; 2024 Jan; 90(1):19-36. PubMed ID: 36572064
[TBL] [Abstract][Full Text] [Related]
7. Steroid-Refractory Chronic Graft-Versus-Host Disease: Treatment Options and Nursing Care.
Cazeau N; Rodriguez S
Clin J Oncol Nurs; 2023 May; 27(3):259-265. PubMed ID: 37267484
[TBL] [Abstract][Full Text] [Related]
8. Clinical and economic burden associated with graft-versus-host disease following allogeneic hematopoietic cell transplantation in France.
Michonneau D; Quignot N; Jiang H; Reichenbach D; Kelly M; Burrell A; Zhang X; Thiruvillakkat K; Mohty M
Bone Marrow Transplant; 2023 May; 58(5):514-525. PubMed ID: 36765178
[TBL] [Abstract][Full Text] [Related]
9. Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
Gonzalez RM; Pidala J
Pharmacotherapy; 2020 Aug; 40(8):756-772. PubMed ID: 32441379
[TBL] [Abstract][Full Text] [Related]
10. Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria.
Cuvelier GDE; Nemecek ER; Wahlstrom JT; Kitko CL; Lewis VA; Schechter T; Jacobsohn DA; Harris AC; Pulsipher MA; Bittencourt H; Choi SW; Caywood EH; Kasow KA; Bhatia M; Oshrine BR; Flower A; Chaudhury S; Coulter D; Chewning JH; Joyce M; Savaşan S; Pawlowska AB; Megason GC; Mitchell D; Cheerva AC; Lawitschka A; West LJ; Pan B; Al Hamarneh YN; Halevy A; Schultz KR
Blood; 2019 Jul; 134(3):304-316. PubMed ID: 31043425
[TBL] [Abstract][Full Text] [Related]
11. Incidence, Risk Factors, Characteristics, and Outcome of Chronic Graft Versus Host Disease in Children Undergoing Haploidentical Peripheral Blood Stem Cell Transplant With Post-transplant Cyclophosphamide.
Arora S; Thakkar D; Upasana K; Yadav A; Rastogi N; Sharma PS; Yadav SP
J Pediatr Hematol Oncol; 2024 Jan; 46(1):e44-e50. PubMed ID: 37983773
[TBL] [Abstract][Full Text] [Related]
12. A Multiparameter Prognostic Risk Score of Chronic Graft-versus-Host Disease Based on CXCL10 and Plasmacytoid Dendritic Cell Levels in the Peripheral Blood at 3 Months after Allogeneic Hematopoietic Stem Cell Transplantation.
Chirumbolo G; Dicataldo M; Barone M; Storci G; De Matteis S; Laprovitera N; Sinigaglia B; Barbato F; Maffini E; Cavo M; Bonifazi F; Arpinati M
Transplant Cell Ther; 2023 May; 29(5):302.e1-302.e8. PubMed ID: 36796518
[TBL] [Abstract][Full Text] [Related]
13. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
[TBL] [Abstract][Full Text] [Related]
14. Graft-Versus-Host-Disease and Health-Related Quality of Life in Young Long-term Survivors of Cancer and Allogeneic Hematopoietic Stem Cell Transplantation.
Diep PP; Rueegg CS; Burman MM; Brinch L; Bø K; Fosså K; Landrø L; Loge JH; Lund MB; Massey RJ; Myrdal OH; Pathak M; Rimstad L; Tanem KE; Tjønnfjord GE; Aaløkken TM; Ruud E
J Adolesc Young Adult Oncol; 2023 Feb; 12(1):66-75. PubMed ID: 35544321
[No Abstract] [Full Text] [Related]
15. Targeting Bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in mice.
Chen X; Wang Y; Huang X; Geng S; Li C; Zeng L; Huang L; Du X; Weng J; Lai P
Int Immunopharmacol; 2023 Apr; 117():109746. PubMed ID: 36827923
[TBL] [Abstract][Full Text] [Related]
16. Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials.
DeFilipp Z; Kim HT; Yang Z; Noonan J; Blazar BR; Lee SJ; Pavletic SZ; Cutler C
Blood Adv; 2022 Dec; 6(24):6263-6270. PubMed ID: 36083121
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of oral chronic graft-versus-host disease according to the 2014 National Institutes of Health (USA) consensus criteria.
Pengpis N; Prueksrisakul T; Chanswangphuwana C
Med Oral Patol Oral Cir Bucal; 2023 Mar; 28(2):e167-e173. PubMed ID: 36173715
[TBL] [Abstract][Full Text] [Related]
18. Ocular graft-versus-host disease (oGVHD): From A to Z.
Soleimani M; Mahdavi Sharif P; Cheraqpour K; Koganti R; Masoumi A; Baharnoori SM; Salabati M; Djalilian AR
Surv Ophthalmol; 2023; 68(4):697-712. PubMed ID: 36870423
[TBL] [Abstract][Full Text] [Related]
19. The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease.
Cooke KR; Luznik L; Sarantopoulos S; Hakim FT; Jagasia M; Fowler DH; van den Brink MRM; Hansen JA; Parkman R; Miklos DB; Martin PJ; Paczesny S; Vogelsang G; Pavletic S; Ritz J; Schultz KR; Blazar BR
Biol Blood Marrow Transplant; 2017 Feb; 23(2):211-234. PubMed ID: 27713092
[TBL] [Abstract][Full Text] [Related]
20. ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease.
Hamad N; Bilmon I; Chee L; Henden A; Johnston A; Purtill D; Bajel A; Tey SK; Yeung D; Cole T; Lewis C; Butler J
Intern Med J; 2023 Dec; 53(12):2319-2329. PubMed ID: 38014511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
